1,824 results on '"Zile, Michael R"'
Search Results
2. Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
3. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure
4. A Novel Heart Failure Diagnostic Risk Score Using a Minimally Invasive Subcutaneous Insertable Cardiac Monitor
5. Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension
6. Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial
7. Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction
8. Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction
9. Abstract 16755: Changes in Mid-Regional Pro-Adrenomedullin During Treatment With Sacubitril/Valsartan
10. Abstract 13828: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARADIGM-HF Proteomic Sub-Study
11. Abstract 12470: Sacubitril/Valsartan in Patients With Heart Failure and Deterioration of Kidney Function to Estimated Glomerular Filtration Rate Less Than 30ml/min/1.73m2: Insights From PARAGON-HF and PARADIGM-HF
12. Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial
13. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan
14. Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides
15. Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure
16. Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure
17. Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction
18. Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation
19. Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
20. Left Ventricular Gene Expression in Heart Failure With Preserved Ejection Fraction—Profibrotic and Proinflammatory Pathways and Genes
21. Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m2
22. In vivo fluid dynamics of the Ventura interatrial shunt device in patients with heart failure
23. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis
24. Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long‐term outcomes
25. Interatrial shunt therapy in advanced heart failure: Outcomes from the open‐label cohort of the RELIEVE‐HF trial
26. 426 A Beat Away from Precision Medicine: Characterizing Human Cardiac Fibroblast Responsiveness to Hemodynamic Unloading in Heart Failure with Reduced Ejection Fraction
27. Hemodynamically-Guided Management of Heart Failure Across the Ejection Fraction Spectrum: The GUIDE-HF Trial
28. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
29. Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF
30. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial
31. Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial
32. Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction
33. In Memoriam—William H. Gaasch, MD, 1937-2022
34. Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON‐HF study
35. Role of Macrophages in Regression of Myocardial Fibrosis Following Alleviation of Left Ventricular Pressure Overload
36. Left ventricle function and post-transcriptional events with exercise training in pigs
37. Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction
38. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial
39. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE
40. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction
41. Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion
42. Incidence and Outcomes of Pneumonia in Patients With Heart Failure
43. Racial difference in atrial size and extracellular matrix homeostatic response to hypertension: Is this a potential mechanism of reduced atrial fibrillation in African Americans?
44. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial
45. Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation
46. Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction
47. Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF.
48. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials
49. Changes in Myocardial Microstructure and Mechanics With Progressive Left Ventricular Pressure Overload
50. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.